arrow
H

Holly E. Barker

walter and eliza hall institute of medical research
H指数:21
被引数:5,576

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma
2026-01-060
OAAI
Farletuzumab ecteribulin and MORAb-109, folate receptor alpha and mesothelin targeting antibody-drug conjugates, show activity in poor prognosis gynaecological cancer models

Farletuzumab ecteribulin和MORAb-109,靶向叶酸受体α和间皮素的抗体-药物偶联物,在预后不良的妇科癌症模型中显示出活性。

2025-03-120
OA
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
2024-08-050
OAAI
A risk-reward examination of sample multiplexing reagents for single cell RNA-Seq
2024-03-015
OAAI
SF3B1 hotspot mutations confer sensitivity to PARP inhibition through a defective replication stress response
2023-12-010
PRE
The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models

微管抑制剂eribulin在铂耐药和难治性高级浆液性卵巢癌患者来源的异种移植模型中显示出疗效

2023-11-221
OAAI
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response
2023-07-3118
OAAI
Targeting homologous recombination deficiency in uterine leiomyosarcoma

靶向子宫平滑肌肉瘤的同源重组缺陷

2023-05-0410
OAAI
Mutations in the RNA Splicing Factor SF3B1 drive endocrine therapy resistance and confer a targetable replication stress response defect through PARP inhibition
2023-03-010
PRE
Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
2022-10-0710
OAAI
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer
2021-02-1510
OA